PYTEST® 14C-Urea Breath Test + VOQUEZNA® Triple Pak®
ApprovedActive 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
H Pylori Infection
Conditions
H Pylori Infection, H Pylori Gastritis, Gastric Cancer
Trial Timeline
Oct 15, 2022 → Nov 6, 2027
NCT ID
NCT07224035About PYTEST® 14C-Urea Breath Test + VOQUEZNA® Triple Pak®
PYTEST® 14C-Urea Breath Test + VOQUEZNA® Triple Pak® is a approved stage product being developed by Phathom Pharmaceuticals for H Pylori Infection. The current trial status is active. This product is registered under clinical trial identifier NCT07224035. Target conditions include H Pylori Infection, H Pylori Gastritis, Gastric Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07224035 | Approved | Active |
Competing Products
7 competing products in H Pylori Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy | Sun Pharmaceutical | Approved | 85 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + Placebo + helicobacter pylori vaccine + helicobacter pylori vaccine | Novartis | Phase 1 | 33 |
| H.pylori vaccines + Placebo Vaccine | Novartis | Phase 1 | 33 |
| PYTEST® 14C-Urea Capsule Breath Test (at Home) + PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person) | Phathom Pharmaceuticals | Approved | 80 |
| Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| RHB-105 + Active Comparator | RedHill Biopharma | Phase 3 | 69 |